ARTICLE | Clinical News
MIN-117: Phase IIa data
May 30, 2016 7:00 AM UTC
Top-line data from a double-blind, European Phase IIa trial in 84 patients with moderate to severe MDD showed that once-daily 0.5 and 2.5 mg oral MIN-117 for 6 weeks improved MADRS total score by magn...